FDA Approves Drug Combo for Aggressive Thyroid Cancer

Share this content:
FDA Approves Drug Combo for Aggressive Thyroid Cancer
FDA Approves Drug Combo for Aggressive Thyroid Cancer

MONDAY, May 7, 2018 (HealthDay News) -- Two anti-cancer drugs administered together have been approved by the U.S. Food and Drug Administration to treat BRAF-positive anaplastic thyroid cancer.

Tafinlar (dabrafenib) and Mekinist (trametinib) combined have been approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene, the agency said Friday in a news release. The same drug combination was approved previously to treat melanoma and non-small-cell lung cancer caused by abnormalities of the same gene.

Common side effects of the drug combination include: fever, rash, chills, headache, arthralgia, cough, fatigue, nausea, and diarrhea, the FDA said. More serious adverse reactions could include: development of new cancers, bleeding problems, heart problems, eye problems, skin reactions, high blood sugar, anemia, and blood clots. Since both drugs can harm a growing fetus, pregnant women and women who are expecting to become pregnant shouldn't take the therapy, the agency warned.

"This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and the third cancer with this specific gene mutation that this drug combination has been approved to treat," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients."

Both drugs are produced by the Swiss drugmaker Novartis Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »